sur Fortvita Biologics
Fortvita Biologics Gets Positive Opinion on Lung Cancer Treatment
Fortvita Biologics has received its first positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This opinion recommends the marketing authorization of Zybrivo® (sintilimab) for first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in eligible adults. If approved by the European Commission, this drug will expand treatment options across Europe.
The recommendation is based on Phase 3 ORIENT-11 study results, which demonstrated a significant reduction in disease progression risk when sintilimab was combined with chemotherapy. The study involved 397 participants with advanced or metastatic non-squamous NSCLC, showing improved progression-free and overall survival rates compared to placebo.
Zybrivo, combined with chemotherapy, showed a 52% reduction in disease progression risk. If approved, it will be available in EU member states, Iceland, Norway, and Liechtenstein. This milestone highlights Fortvita's commitment to expanding access to innovative therapies globally.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Fortvita Biologics